Back HIV Prevention

EACS 2013: Ensuring Good Quality HIV Care in Europe: Where Can We Improve?

Only 20% of people with HIV in Europe have fully suppressed viral load, compared to an estimated 24% in sub-Saharan Africa, despite much higher rates of HIV diagnosis in the European region, Professor Jens Lundgren of the University of Copenhagen told the 14th European AIDS Conference in Brussels on Saturday.

alt

Read more:

Coverage of the 14th European AIDS Conference

HIVandHepatitis.com coverage of the 14th European AIDS Conference, sponsored by the European AIDS Clinical Society (EACS), October 16-19, 2013, in Brussels.

Conference highlights include antiretroviral therapy strategies and new HIV drugs, new treatment for hepatitis C, biomedical HIV prevention, HIV cure research, and the epidemic in Eastern Europe.

Full listing by topic

10/20/13

alt

 

 

IDWeek 2013: HIV+ People Not on Antiretrovirals Are Prone to Inflammation-related Bone Loss

HIV positive people not taking antiretroviral therapy experienced more bone mineral density (BMD) loss at the hip and were somewhat more likely to develop osteopenia or osteoporosis than HIV negative individuals, researchers reported at the second IDWeek conference held recently in San Francisco. They also found that bone loss among people with HIV appeared to be linked to inflammation.

alt

Read more:

EACS 2013: Dual Therapy with Kaletra + Lamivudine Works Well Regardless of Viral Load

A dual combination of lopinavir/ritonavir (Kaletra or Aluvia) plus lamivudine (3TC or Epivir) as first-line therapy produced good virological suppression regardless of baseline viral load and was well-tolerated in the multinational GARDEL study, according to a late-breaking report at the 14thEuropean AIDS Conference this week in Brussels.

alt

Read more:

AIDS Vaccine 2013: HIV Vaccines Disappointing So Far But Necessary to Control Epidemic

Since the first diagnosis of HIV in humans 30 years ago, there have been many scientific discoveries to slow and possibly curb the spread of the epidemic. However while some approaches have been highly successful, vaccines have not offered so much hope or good news.

As the AIDS Vaccine 2013 conference last week in Barcelona came to an end after a 4-day intensive of presentations and dialog on the place of vaccines in the HIV field, many questions were left unanswered.

alt

Read more:

EACS 2013: GSK1265744 Rapidly Suppresses HIV, Appears Safe At Selected Dose

The experimental HIV integrase inhibitor GSK1265744 demonstrated rapid and potent antiviral activity and good tolerability for treatment-naive patients in the LATTE study, according to a report at the 14th European AIDS Conference this week in Brussels.

alt

Read more:

October 15 is National Latino AIDS Awareness Day

National Latino AIDS Awareness Day(NLAAD), recognized annually on October 15, is opportunity to raise awareness about the HIV/AIDS epidemic among Latino and Hispanic people in the U.S. According to the Centers for Disease Control and Prevention (CDC), while Latinos/Hispanics make up approximately 16% of the total U.S. population, they accounted for 20% of all new HIV infections in 2009.

alt

Read more:

European AIDS Conference Features Latest HIV & Hepatitis C Data, New Guidelines

The European AIDS Conference, the biennial meeting of the European AIDS Clinical Society (EACS), opened Wednesday in Brussels, the site of the organization's first meeting 25 years ago. The conference included the latest news on antiretroviral therapy (ART) for HIV, hepatitis C treatment for HIV/HCV coinfected people, and biomedical HIV prevention, as well as the launch of updated European treatment guidelines.

alt

Read more:

European AIDS Conference Opens this Week in Brussels

The 14th European AIDS Conference, the biennial meeting of the European AIDS Clinical Society (EACS), takes place this week in Brussels. EACS 2013 will immediately follow the 15th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, and will hold joint sessions on the hepatitis C treatment revolution and managing complications such as cardiovascular disease and osteoporosis.

alt

Read more:

EACS 2013: New European Treatment Guidelines Strike Balance Between Individual Choice and Public Health

A new edition of the European AIDS Clinical Society (EACS) guidelines for the treatment of HIV, HIV/hepatitis C coinfection, and HIV with other comorbidities were published in advance of the 14th European AIDS Conference currently taking place in Brussels and were presented and discussed at a special session and press conference Friday.

alt

Read more:

IDWeek 2013: HIV+ Transwomen Not Getting the Maximum Benefits of Care

More than three-quarters of HIV positive transgender women in San Franciscowere linked to care and 65% are taking antiretroviral therapy (ART), but only 44% achieve viral suppression, according to findings presented* at the recent Second IDWeek conference in San Francisco and in the American Journal of Public Health. A larger national survey, however, found that 68% of transgender people reached undetectable viral load.

alt

Read more:

EACS 2013: Experts Debate Whether HIV Cure Is "Hype or Hope"

Is a functional cure for HIV feasible within the foreseeable future, or is it a hopeless quest robbing resources from more practical approaches to improve the lives of people living with HIV? This question was the crux of a mock trial held Wednesday on the opening day of the 14th European AIDS Conference (EACS 2013) in Brussels.

alt

Read more:

Support for Adherence Improves PrEP's Protective Effect Against HIV

Adherence monitoring and counseling can help people use Truvada pre-exposure prophylaxis (PrEP) consistently, leading to a high degree of protection against HIV infection, according to the latest findings from the Partners PrEP trial, published online September 10, 2013, in PLoS Medicine.

alt

Read more:

EACS 2013: Anal Cancer Screening May Be Appropriate for All Women with HIV

Women living with HIV had a higher risk of anal pre-cancerous changes than cervical changes linked to human papillomavirus (HPV), French researchers reported at the 14th European AIDS Conference this week in Brussels. They suggested that all women with HIV ought to be screened routinely for pre-cancerous changes in the anal canal.

alt

Read more:

IDWeek 2013: Complera Works Well Regardless of Viral Load or CD4 Count, Improves Lipid Levels

The single-tablet regimen Complera (rilpivirine/tenofovir/emtricitabine) worked as well as Atripla (efavirenz/tenofovir/emtricitabine) for treatment-naive people across a range of viral load and CD4 T-cell levels, researchers reported at the Second IDWeek conference last week in San Francisco. Another study found that switching from a boosted protease inhibitor to Complera lowered cholesterol and triglyceride levels.

alt

Read more:

EACS 2013: Cenicriviroc Shows Good Activity Against HIV, New Formulation May Reduce Dropouts

The dual CCR5/CCR2 inhibitor cenicriviroc demonstrated good antiviral activity and tolerability in a Phase 2 clinical trial, according to a report at the 14th European AIDS Conference (EACS 2013) this week in Brussels. The study had many dropouts, likely due to its complex dosing regimen, but a more user-friendly cenicriviroc formulation has since been developed.

alt

Read more:

Definition of Brave: Long Term Survivors Reunite at Town Hall Forum in San Francisco

The AIDS generation has come alive again. It was apparent in the collective wisdom of over 175 AIDS survivors and their supporters and loved ones gathered in the packed Rainbow Room at San Francisco’s LGBT Center on September 16.

Over the past several months, Tez Anderson and several local AIDS activists had been organizing the town hall forum, entitled "Definition of Brave." The forum was organized to begin to understand and address a series of problems including severe depression, isolation, and suicide -- all related to living through and surviving AIDS for 20 years or more. 

alt

Read more:

EACS 2013: EACS Condemns Impact of Russian Anti-Gay Law on HIV Prevention and Care

The European AIDS Clinical Society (EACS) has strongly condemned the discriminatory legal and policy environment being promoted by Russian politicians against gay men, lesbians and transgender people.

alt

Read more:

IDWeek 2103: The Past, Present, and Future of HIV Treatment

More that 25 years after approval of the first antiretroviral drug -- AZT in 1987 -- several presenters at the 2nd IDWeek meeting last week in San Franciscodiscussed the history, state-of-the-art, and future of HIV treatment. Modern antiretroviral therapy (ART) has kep countless people alive, but researchers and people with HIV are now looking toward biomedical prevention and ultimately a cure.

alt

Read more:

EACS 2013: Researchers and Advocates Discuss Biomedical HIV Prevention

The first day of the European AIDS Conference (EACS 2013), which opened yesterday in Brussels, featured a satellite symposium on development of HIV microbicides, broadly defined to include a variety of approaches to pre-exposure prophylaxis (PrEP).

alt

Read more:

Coverage of IDWeek 2013

HIVandHepatitis.com coverage of the Second ID Week, October 2-6, in San Francisco.

Conference highlights include antiretroviral therapy strategies, investigational agents for HIV and hepatitis C, management of HIV-related complications, biomedical HIV prevention, and HIV cure research.

Full listing by topic

10/8/13

alt